Ardiden appoints former Triton Minerals executive

|

Published 17-FEB-2016 14:54 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The man who helped Triton Minerals (ASX:TON) bag a $2 billion offtake deal is now the executive director of Ardiden Ltd (ASX:ADV).

Brad Boyle is heading to the ASX-listed graphite and lithium junior and his appointment is likely a statement of intent from the company, given Boyle’s TON experience.

Not only was he CEO when the company secured a $2 billion offtake deal last year, but Boyle also played a role in the identification and development of the Nicanda Hill project in Mozambique underpinning the deal.

Boyle also reportedly has extensive material in negotiating with end-users, including manufacturers of lithium-ion batteries.

Brad Boyle, executive director at Ardiden Ltd

Brad Boyle, executive director at Ardiden Ltd

Meanwhile, ADV has appointed Canadian industry veteran Michael Stares as its general manager of Canadian Operations.

Stares has spent the past 30 years working in the mineral industry in Canada, and is based in the key export area of Thunder Bay.

The appointment could be read as reward for previous service to the company, as he helped discover ADV’s flagship Silver Star North deposit at the Manitouwadge project.

Silver Star North has been pegged by the company as the key target for delineating a maiden JORC resource.

Interestingly, he is also familiar with the lithium projects ADV recently secured under option to acquire 100%.

About ADV

Ardiden Ltd (ASX:ADV) has set itself up as a diversified miner targeting both graphite and lithium for supply into the lithium-ion battery industry.

Its main play is the Manitouwadge graphite project, which is made up of several prospects such as the Silver Star North, Silver Star South, and Thomas Lake.

It is thought the Sliver Star North prospect will form the basis of a maiden JORC resource for the company, which is due this year.

Elsewhere, it has picked up options to acquire 100% stakes in two lithium assets, also in Canada.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X